Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739411 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized Imaging in Diagnosing Participants With Glioma
A Phase 1 study of Glioma, sponsored by Susan Chang.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT03739411 is a Phase 1 study of Glioma that is actively recruiting participants, run by Susan Chang. The registered enrollment target is 140 participants, below the 208-participant average among 87 other Glioma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03739411, a Phase 1 study of Glioma, is actively recruiting participants, sponsored by Susan Chang.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- RADIATION Radiation Therapy
- DRUG Chemotherapy
- RADIATION Hyperpolarized Carbon C 13 Pyruvate
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-12-09 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739411
The ClinicalTrials.gov registry entry for NCT03739411 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 87 other Glioma trials with a reported enrollment target (33% lower). The listed sponsor is Susan Chang, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT03739411 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03739411 about?
NCT03739411 is a clinical study titled "Hyperpolarized Imaging in Diagnosing Participants With Glioma". This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
What is the current status of trial NCT03739411?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2015-12-09. Estimated completion is 2028-06-01.
What conditions does trial NCT03739411 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT03739411?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Radiation Therapy (RADIATION), Chemotherapy (DRUG), Hyperpolarized Carbon C 13 Pyruvate (RADIATION).
Who is sponsoring clinical trial NCT03739411?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03739411 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.